Safety and efficacy of discontinuation and re-administration of infliximab after long term continuous therapy in patients with ankylosing spondylitis

被引：0
|
作者：
Baraliakos, X. [1 ]
Listing, J. [1 ]
Brandt, J. [1 ]
Sieper, J. [1 ]
Braun, J. [1 ]
机构：
[1] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet, D-4630 Bochum, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
137
引用
收藏
页码：A44 / A44
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis
    Baraliakos, Xenofon
    Listing, Joachim
    Rudwaleit, Martin
    Brandt, Jan
    Alten, Rieke
    Burmester, Gerd
    Gromnica-Ihle, Erika
    Haibel, Hildrun
    Schewe, Stephan
    Schneider, Matthias
    Soerensen, Helmut
    Zeidler, Henning
    Visvanathan, Sudha
    Sieper, Joachim
    Braun, Juergen
    [J]. JOURNAL OF RHEUMATOLOGY, 2007, 34 (03) : 510 - 515
  • [2] Long-term efficacy and safety of infliximab treatment of ankylosing spondylitis
    Boeger, CA
    Wittwer, H
    Schattenkirchner, M
    Kellner, M
    [J]. JOURNAL OF RHEUMATOLOGY, 2001, 28 : 64 - 64
  • [3] Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
    Elalouf, Ofir
    Elkayam, Ori
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 1719 - 1726
  • [4] CLINICAL EFFICACY AND SAFETY OF INFLIXIMAB - FIRST RESULTS AFTER A DECADE OF CONTINUOUS TREATMENT IN ANKYLOSING SPONDYLITIS
    Baraliakos, X.
    Listing, J.
    Fritz, C.
    Haibel, H.
    Alten, R.
    Burmester, G.
    Krause, A.
    Schewe, S.
    Schneider, M.
    Soerensen, H.
    Schmidt, R.
    Sieper, J.
    Braun, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 252 - 252
  • [5] Real-world efficacy of dupilumab re-administration after discontinuation in patients with atopic dermatitis
    Matsutani, Masako
    Imai, Yasutomo
    Miyamoto, Shoko
    Inoue, Yukako
    Natsuaki, Masaru
    Kanazawa, Nobuo
    [J]. JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2024, 7
  • [6] Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
    Baraliakos, X
    Listing, J
    Brandt, J
    Rudwaleit, M
    Sieper, J
    Braun, J
    [J]. ARTHRITIS RESEARCH & THERAPY, 2005, 7 (03) : R439 - R444
  • [7] Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
    Xenofon Baraliakos
    Joachim Listing
    Jan Brandt
    Martin Rudwaleit
    Joachim Sieper
    Juergen Braun
    [J]. Arthritis Research & Therapy, 7
  • [8] Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
    Brandt, J
    Listing, J
    Haibel, H
    Sörensen, H
    Schwebig, A
    Rudwaleit, M
    Sieper, J
    Braun, J
    [J]. RHEUMATOLOGY, 2005, 44 (03) : 342 - 348
  • [9] The efficacy and safety of re-administration of rasburicase for patients with hematological malignancies
    Imamura, Kyoko
    Sugiyama, Keiji
    Hasegawa, Yuta
    Nakamura, Hiroyuki
    Suzuki, Yasuhiro
    Tokunaga, Takashi
    Miyata, Yasuhiko
    Kunitomi, Akane
    Iida, Hiroatsu
    Nagai, Hirokazu
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] THE INFLIXIMAB EFFICACY AND TOLERABILITY ANALYSIS AFTER THE FORCED THERAPY INTERRUPTION IN PATIENTS WITH ANKYLOSING SPONDYLITIS
    Rumyantseva, O. A.
    Kuzikyants, K. H.
    Bochkova, A. G.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : 618 - 618
12345